Presumably, combinations of the inhibitors with standard chemotherapeutic agents or targeted therapies might improve the anti-tumor potency of the HSP-inhibitors even at lower concentrations and thereby reduce their side effects. The gene discussed is HSP90B2P; the disease is neoplasm.